Anaprox or Anaprox DS (naproxen sodium) is indicated for:

• The relief of mild to moderately severe pain, accompanied by inflammation in conditions such as musculo skeletal trauma and post-dental extraction.
• The relief of pain associated with post-partum cramping and dysmenorrhea.

For complete prescribing information, please consult the Product Monograph.

Fucithalmic Viscous Eye Drops (fusidic acid) are indicated for the treatment of superficial infections of the eye and its adnexa (ie., conjunctivitis) caused by fusidic acid susceptible strains of the designated bacteria in adults and children (≥2 years of age): Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae.

For complete prescribing information, please consult the Product Monograph.

Naprosyn (naproxen) is indicated for:

• The treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
• The relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in musculoskeletal injuries (sprains and strains) and primary dysmenorrhea.

For complete prescribing information, please consult the Product Monograph.

Resotran (prucalopride succinate tablets) is indicated for the treatment of chronic idiopathic constipation in adult female patients in whom
laxatives failed to provide adequate relief.

For complete prescribing information, please consult the Product Monograph.

Salagen (Pilocarpine Hydrochloride Tablets) is indicated for:

• the treatment of the symptoms of xerostomia (dry mouth) due to salivary gland hypofunction caused by radiotherapy for cancer of the head and neck,
• the treatment of the symptoms of xerostomia (dry mouth) and xerophthalmia (dry eyes) in patients with Sjögren’s syndrome

For complete prescribing information, please consult the Product Monograph.

Xermelo (telotristat ethyl) is indicated for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone.

For complete prescribing information, please consult the Product Monograph. Please note that Xermelo is distributed to patients through a restricted distribution system. For information on Xermelo’s patient support program, and to obtain information on accessing the product, please contact (289) 383-1933 or fax 1 (866) 417-1945.